Quantitative proteomic analysis in breast cancer

Drugs of Today

Volumn 47, Issue 2, 2011, Pages 169-182

  Tabchy, Adel ^a   Hennessy, B T ^a   Gonzalez Angulo, A M ^a   Bernstam, F M ^a   Lu, Y ^a   Mills, G B ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA;

BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER PATIENT; COPY NUMBER VARIATION; DOUBLE ANTIBODY SANDWICH ENZYME LINKED IMMUNOSORBENT ASSAY; FUNCTIONAL PROTEOMICS; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; GENE SEQUENCE; HIGH THROUGHPUT SCREENING; HUMAN; LIQUID CHROMATOGRAPHY; PATIENT MONITORING; PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN CONFORMATION; PROTEIN MICROARRAY; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; REVIEW; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; WESTERN BLOTTING;

BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; FEMALE; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; PROGNOSIS; PROTEIN ARRAY ANALYSIS; PROTEOMICS; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; TUMOR MARKERS, BIOLOGICAL; TUMOR MICROENVIRONMENT;

EID: 79955941549     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2011.47.2.1576695     Document Type: Review

References (88)

1. Nishizuka, S., Charboneau, L., Young, L. et al. Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc Natl Acad Sci U S A 2003, 100(24): 14229-34.
2. Sørlie, T., Perou, C.M., Tibshirani, R. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001, 98(19): 10869-74.
3. van de Vijver, M.J., He, Y.D., van't Veer, L.J. et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347(25): 1999-2009.
4. Ayers, M., Symmans, W.F., Stec, J. et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 2004, 22(12): 2284-93.
5. Wulfkuhle, J.D., Edmiston, K.H., Liotta, L.A., Petricoin, E.F. 3rd. Technology insight: pharmacoproteomics for cancer - promises of patient-tailored medicine using protein microarrays. Nat Clin Pract Oncol 2006, 3(5): 256-68.
6. Liotta, L.A., Espina, V., Mehta, A.I. et al. Protein microarrays: Meeting analytical challenges for clinical applications. Cancer Cell 2003, 3(4): 317-25.
7. American Cancer Society: Breast Cancer Facts and Figures 2009-2010. http://www.cancer.org/downloads/STT/F861009-final%209-08-09.pdf.
8. Cox, J, Mann, M. Is proteomics the new genomics? Cell 2007, 130(3): 395-8.
9. Krutchinsky, A.N., Kalkum, M., Chait, B.T. Automatic identification of proteins with a MALDI-quadruple ion trap mass spectrometer. Anal Chem 2001, 73(21): 5066-77.
10. Faca, V., Pitteri, S.J., Newcomb, L. et al. Contribution of protein fractionation to depth of analysis of the serum and plasma proteomes. J Proteome Res 2007, 6(9): 3558-65.
11. Medintz, I.L., Uyeda, H.T., Goldman, E.R., Mattoussi, H. Quantum dot bioconjugates for imaging, labelling and sensing. Nat Mater 2005, 4(6): 435-46.
12. Tada, H., Higuchi, H., Wanatabe, T.M., Ohuchi, N. In vivo real-time tracking of single quantum dots conjugated with monoclonal anti-HER2 antibody in tumors of mice. Cancer Res 2007, 67(3): 1138-44.
13. Bailey, R., Kris, M., Wolf, M. et al. O-242 Gefitinib (Iressa[TM], ZD-1839) monotherapy for pretreated advanced non-small cell lung cancer in IDEAL 1 and 2: Tumor response is not clinically relevantly predictable from tumor EGFR membrane staining alone. Lung Cancer 2003, 41: S71.
14. Press, M.F., Slamon, D.J., Flom, K.J., Park, J., Zhou, J.Y., Bernstein, L. Evaluation of HER-2/neu gene amplification and overexpression: Comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 2002, 20(14): 3095-105.
15. Leader, M., Patel, J., Makin, C., Henry, K. An analysis of the sensitivity and specificity of the cytokeratin marker CAM 5.2 for epithelial tumours. Results of a study of 203 sarcomas, 50 carcinomas and 28 malignant melanomas. Histopathology 1986, 10(12): 1315-24.
16. Press, M.F., Sauter, G., Bernstein, L. et al. Diagnostic evaluation of HER-2 as a molecular target: An assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res 2005, 11(18): 6598-607.
17. LaBaer, J., Ramachandran, N. Protein microarrays as tools for functional proteomics. Curr Opinion Chem Biol 2005, 9(1): 14-9.
18. MacBeath, G., Schreiber, S.L. Printing proteins as microarrays for high-throughput function determination. Science 2000, 289(5485): 1760-3.
19. Espina, V., Mehta, A.I., Winters, M.E., Calvert, V., Wulfkuhle, J., Petricoin, E.F. 3rd, Liotta, L.A. Protein microarrays: Molecular profiling technologies for clinical specimens. Proteomics 2003, 3(11): 2091-100.
20. Sheehan, K.M., Calvert, V.S., Kay, E.W. et al. Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol Cell Proteomics 2005, 4(4): 346-55.
21. Görg, A., Weiss, W., Dunn, M.J. Current two-dimensional electrophoresis technology for proteomics. Proteomics 2004, 4(12): 3665-85.
22. Washburn, M.P., Wolters, D., Yates, J.R. 3rd. Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat Biotechnol 2001, 19(3): 242-7.
23. Paweletz, C.P., Charboneau, L., Bichsel, V.E. et al. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 2001, 20(16): 1981-9.
24. Petricoin, E.F. 3rd, Bichsel, V.E., Calvert, V.S. et al. Mapping molecular networks using proteomics: A vision for patient-tailored combination therapy. J Clin Oncol 2005, 23(15): 3614-21.
25. Wulfkuhle, J.D., Aquino, J.A., Calvert, V.S., Fishman, D.A., Coukos, G., Liotta, L.A., Petricoin, E.F. 3rd. Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays. Proteomics 2003, 3(11): 2085-90.
26. Gulmann, C., Espina, V., Petricoin, E. 3rd et al. Proteomic analysis of apoptotic pathways reveals prognostic factors in follicular lymphoma. Clin Cancer Res 2005, 11(16): 5847-55.
27. Hennessy, B.T., Lu, Y., Gonzalez-Angulo, A.M. et al. A technical assessment of the utility of reverse phase protein arrays for the study of the functional proteome in non-microdissected human breast cancers. Clin Proteomics 2010, 6(4): 129-51.
28. Tibes, R., Qiu, Y., Lu, Y., Hennessy, B., Andreeff, M., Mills, G.B., Kornblau, S.M. Reverse phase protein array (RPPA): Validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther 2006, 5(10): 2512-21.
29. Hennessy, B.T., Lu, Y., Poradosu, E. et al. Pharmacodynamic markers of perifosine efficacy. Clin Cancer Res 2007, 13(24): 7421-31.
30. Cheng, K.W., Lu, Y., Mills, G.B. Assay of Rab25 function in ovarian and breast cancers. Methods Enzymol 2005, 403: 202-15.
31. Charboneau, L., Tory, H., Chen, T., Winters, M., Petricoin, E.F. 3rd, Liotta, L.A., Paweletz, C.P. Utility of reverse phase protein arrays: Applications to signalling pathways and human body arrays. Brief Funct Genomic Proteomic 2002, 1(3): 305-15.
32. Iwamaru, A., Kondo, Y., Iwado, E. et al. Silencing mammalian target of rapamycin signaling by small interfering RNA enhances rapamycin-induced autophagy in malignant glioma cells. Oncogene 2007, 26(13): 1840-51.
33. Espina, V., Edmiston, K.H., Heiby, M. et al. A portrait of tissue phosphoprotein stability in the clinical tissue procurement process. Mol Cell Proteomics 2008, 7(10): 1998-2018.
34. Baker, A.F., Dragovich, T., Ihle, N.T., Williams, R., Fenoglio-Preiser, C., Powis, G. Stability of phosphoprotein as a biological marker of tumor signaling. Clin Cancer Res 2005, 11(12): 4338-40.
35. Agarwal, R., Gonzalez-Angulo, A.M., Myhre, S. et al. Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer. Clin Cancer Res 2009, 15(11): 3654-62.
36. Silvestri, A., Colombatti, A., Calvert, V.S. et al. Protein pathway biomarker analysis of human cancer reveals requirement for upfront cellular-enrichment processing. Lab Invest 2010, 90(5): 787-96.
37. Kalluri, R., Weinberg, R.A. The basics of epithelial-mesenchymal transition. J Clin Invest 2009, 119(6): 1420-8.
38. Sheehan, K.M., Gulmann, C., Eichler, G.S. et al. Signal pathway profiling of epithelial and stromal compartments of colonic carcinoma reveals epithelial-mesenchymal transition. Oncogene 2008, 27(3): 323-31.
39. Stemke-Hale, K., Gonzalez-Angulo, A.M., Lluch, A. et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 2008, 68(15): 6084-91.
40. Wulfkuhle, J.D., Speer, R., Pierobon, M. et al. Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy. J Proteome Res 2008, 7(4): 1508-17.
41. VanMeter, A.J., Rodriguez, A.S., Bowman, E.D. et al. Laser capture microdissection and protein microarray analysis of human non-small cell lung cancer: Differential epidermal growth factor receptor (EGPR) phosphorylation events associated with mutated EGFR compared with wild type. Mol Cell Proteomics 2008, 7(10): 1902-24.
42. Rikova, K., Guo, A., Zeng, Q. et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007, 131(6): 1190-203.
43. Vasudevan, K.M., Barbie, D.A., Davies, M.A. et al. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell 2009, 16(1): 21-32.
44. Dillon, R.L., Marcotte, R., Hennessy, B.T., Woodgett, J.R., Mills, G.B., Muller, W.J. Akt1 and akt2 play distinct roles in the initiation and metastatic phases of mammary tumor progression. Cancer Res 2009, 69(12): 5057-64.
45. Slamon, D.J., Leyland-Jones, B., Shak, S. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344(11): 783-92.
46. Thor, A.D., Liu, S., Edgerton, S. et al. Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): A study of incidence and correlation with outcome in breast cancer. J Clin Oncol 2000, 18(18): 3230-9.
47. Lynch, T.J., Bell, D.W., Sordella, R. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350(21): 2129-39.
48. Paez, J.G., Jänne, P.A., Lee, J.C. et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004, 304(5676): 1497-500.
49. Sordella, R., Bell, D.W., Haber, D.A., Settleman, J. Gefitinib- sensitizing EGFR mutations in lung cancer activate antiapoptotic pathways. Science 2004, 305(5687): 1163-7.
50. Takano, T., Ohe, Y., Sakamoto, H. et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005, 23(28): 6829-37.
51. Pao, W., Wang, T.Y., Riely, G.J. et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005, 2(1): e17.
52. Khambata-Ford, S., Garrett, C.R., Meropol, N.J. et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007, 25(22): 3230-7.
53. Mellinghoff, I.K., Wang, M.Y., Vivanco, I. et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005, 353(19): 2012-24.
54. Perou, C.M., Sørlie, T., Eisen, M.B. et al. Molecular portraits of human breast tumours. Nature 2000, 406(6797): 747-52.
55. Tabchy, A., Hennessy, B.T., Hortobagyi, G.N., Mills, G.B. Systems biology of breast cancer. Curr Breast Cancer Rep 2009, 1(4): 238-45.
56. Andre, F., Job, B., Dessen, P. et al. Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res 2009, 15(2): 441-51.
57. Eisen, M.B., Spellman, P.T., Brown, P.O., Botstein, D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 1998, 95(25): 14863-8.
58. Ross, J.S., Hatzis, C., Symmans, W.F., Pusztai, L., Hortobágyi, G.N. Commercialized multigene predictors of clinical outcome for breast cancer. Oncologist 2008, 13(5): 477-93.
59. Marchionni, L., Wilson, R.F., Wolff, A.C., Marinopoulos, S., Parmigiani, G., Bass, E.B., Goodman, S.N. Systematic review: Gene expression profiling assays in early-stage breast cancer. Ann Intern Med 2008, 148(5): 358-69.
60. Paik, S., Shak, S., Tang, G. et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004, 351(27): 2817-26.
61. Habel, L.A., Shak, S., Jacobs, M.K. et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res 2006, 8(3): R25-7.
62. Harris, L., Fritsche, H., Mennel, R. et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007, 25(33): 5287-312.
63. Boyd, Z.S., Wu, Q.J., O'Brien, C. et al. Proteomic analysis of breast cancer molecular subtypes and biomarkers of response to targeted kinase inhibitors using reverse-phase protein microarrays. Mol Cancer Ther 2008, 7(12): 3695-706.
64. Hennessy, B.T., Gonzalez-Angulo, A.M., Stemke-Hale, K. et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res 2009, 69(10): 4116-24.
65. The Human Protein Atlas. http://www.proteinatlas.org/
66. Sawyers, C.L. The cancer biomarker problem. Nature 2008, 452(7187): 548-52.
67. Shah, N.P., Nicoll, J.M., Nagar, B., Gorre, M.E., Paquette, R.L., Kuriyan, J., Sawyers, C.L. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002, 2(2): 117-25.
68. States, D.J., Omenn, G.S., Blackwell, T.W., Fermin, D., Eng, J., Speicher, D.W., Hanash, S.M. Challenges in deriving high-confidence protein identifications from data gathered by a HUPO plasma proteome collaborative study. Nat Biotechnol 2006, 24(3): 333-8.
69. Zhang, H., Liu, A.Y., Loriaux, P., Wollscheid, B., Zhou, Y., Watts, J.D., Aebersold, R. Mass spectrometric detection of tissue proteins in plasma. Mol Cell Proteomics 2007, 6(1): 64-71.
70. Jiang, H., English, A.M. Quantitative analysis of the yeast proteome by incorporation of isotopically labeled leucine. J Proteome Res 2002, 1(4): 345-50.
71. Mann, M., Kelleher, N.L. Precision proteomics: The case for high resolution and high mass accuracy. Proc Natl Acad Sci U S A 2008, 105(47): 18132-8.
72. Wolf-Yadlin, A., Hautaniemi, S., Lauffenburger, D.A., White, F.M. Multiple reaction monitoring for robust quantitative proteomic analysis of cellular signaling networks. Proc Natl Acad Sci U S A 2007, 104(14): 5860-5.
73. Elias, J.E., Haas, W., Faherty, B.K., Gygi, S.P. Comparative evaluation of mass spectrometry platforms used in large-scale proteomics investigations. Nat Methods 2005, 2(9): 667-75.
74. Burnette, W.N. "Western blotting": Electrophoretic transfer of proteins from sodium dodecyl sulfate - polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A. Anal Biochem 1981, 112(2): 195-203.
75. Dunbar, S.A., Vander Zee, C.A., Oliver, K.G., Karem, K.L., Jacobson, J.W. Quantitative, multiplexed detection of bacterial pathogens: DNA and protein applications of the Luminex LabMAP system. J Microbiol Methods 2003, 53(2): 245-52.
76. Opalka, D., Lachman, C.E., MacMullen, S.A., Jansen, K.U., Smith, J.F., Chirmule, N., Esser, M.T. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol 2003, 10(1): 108-15. (Pubitemid 36133838)
77. Declerck, P.J., Alessi, M.C., Verstreken, M., Kruithof, E.K., Juhan-Vague, I., Collen, D. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood 1988, 71(1): 220-5.
78. Engvall, E., Perlmann, P. Enzyme-linked immunosorbent assay, Elisa. 3. Quantitation of specific antibodies by enzyme- labeled anti-immunoglobulin in antigen-coated tubes. J Immunol 1972, 109(1): 129-35.
79. Barlogie, B., Raber, M.N., Schumann, J. et al. Flow cytometry in clinical cancer research. Cancer Res 1983, 43(9): 3982-97.
80. Herzenberg, L.A., Parks, D., Sahaf, B., Perez, O., Roederer, M., Herzenberg, L.A. The history and future of the fluorescence activated cell sorter and flow cytometry: A view from Stanford. Clin Chem 2002, 48(10): 1819-27.
81. Pan, S., Aebersold, R., Chen, R. et al. T.A. Mass spectrometry based targeted protein quantification: Methods and applications. J Proteome Res 2009, 8(2): 787-97.
82. Höck, J., Weinmann, L., Ender, C. et al. Proteomic and functional analysis of Argonaute-containing mRNA-protein complexes in human cells. EMBO Rep 2007, 8(11): 1052-60.
83. Lim, J., Crespo-Barreto, J., Jafar-Nejad, P. et al. Opposing effects of polyglutamine expansion on native protein complexes contribute to SCA1. Nature 2008, 452(7188): 713-8.
84. Awdeh, Z.L., Williamson, A.R., Askonas, B.A. Isoelectric focusing in polyacrylamide gel and its application to immunoglobulins. Nature 1968, 219(5149): 66-7.
85. Cui, H. Horiuchi, K., Dutta, P., Ivory, CF. Multistage isoelectric focusing in a polymeric microfluidic chip. Anal Chem 2005, 77(24): 7878-86.
86. Cell Biosciences Firefly™ Protein Analysis System. http://www.cellbiosciences.com/
87. Zeng, Z., Hincapie, M., Haab, B.B. et al. The development of an integrated platform to identify breast cancer glycoproteome changes in human serum. J Chromatogr A 2010, 1217(19): 3307-15.
88. Fan, A.C., Deb-Basu, D., Orban, M.W. et al. Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens. Nat Med 2009, 15(5): 566-71.